Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Immix Biopharma, Inc. Common Stock

IMMX

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Last trade $7.20
Day change -$0.28 (-3.74%)
Day range $7.12 – $7.55
Volume 469,516
Market cap $627M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$626.92M
Price / earnings
—
Price / book
1.87×
Price / sales
—
EV / sales
—
EV / EBITDA
-6.16×

Profitability

Earnings per share
-$0.55
Return on assets
-13.36%
Return on equity
-13.79%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
33.72×
Quick ratio
33.72×
Cash ratio
31.95×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$45.24M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IMMX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$10.4M$7.12M$4.82M$5.17M$3.08M$2.75M$2.71M$3.61M
Research and development$5.54M$5.33M$5.98M$5.73M$4.58M$3.97M$1.98M$1.37M
Total operating expenses$15.95M$12.46M$10.8M$10.89M$7.66M$6.72M$4.68M$4.99M
Operating income-$15.95M-$12.46M-$10.8M-$10.89M-$7.66M-$6.72M-$4.68M-$4.99M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$13.93M-$11.54M-$10.09M-$10.68M-$7.58M-$6.61M-$4.53M-$4.8M
Income taxes$0$14.32K$0$11.27K$7.72K$8.91K$9.82K$10.79K
Net income-$13.93M-$11.56M-$10.09M-$10.69M-$7.59M-$6.62M-$4.54M-$4.81M
Net income attributable to common shareholders-$13.93M-$11.56M-$10.04M-$10.69M-$7.59M-$6.62M-$4.53M-$4.81M
EBITDA-$15.85M-$12.37M-$10.71M-$10.84M-$7.57M-$6.66M-$4.64M-$4.97M
Basic earnings per share-$0.19-$0.18-$0.18-$0.27-$0.24-$0.22-$0.15-$0.15
Diluted earnings per share-$0.19-$0.18-$0.18-$0.27-$0.24-$0.22-$0.15-$0.15

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?

Tenet Healthcare is projected to report Q3 2026 earnings of $4.60 per share (up 24.3% YoY) on revenues of $5.47 billion (up 3.5% YoY). The company's Ambulatory Care segment is expected to drive growth with 8.4% revenue increase and 9.3% adjusted EBITDA growth. However, hospital patient days may decline 3.7% with increased utilization costs partially offsetting gains. The stock has an Earnings ESP of +11.11% and Zacks Rank #3, suggesting a likely earnings beat.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

Pomerantz Law Firm is investigating Immix Biopharma for potential securities fraud after discovering that its newly appointed Chief Medical Officer, Richard Graydon, was actually Ronald L. Fischer, a fugitive wanted for a 2005 rape charge who had evaded authorities for over 20 years. Following the revelation, Immix's stock price dropped 14.15% on July 20, 2026.

GlobeNewswire Inc.

EQPT LAWSUIT: EquipmentShare.com Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses

EquipmentShare.com Inc. (EQPT) faces a securities fraud lawsuit after allegedly making false statements about terminating related-party transactions with founder-controlled entities. A short-seller report revealed undisclosed transactions netting founders at least $77 million, causing the stock to plummet 34.5% below its IPO price. Investors who purchased shares between January 23 and June 23, 2026, may be eligible to recover losses.

GlobeNewswire Inc.

Immix Biopharma Investigated by the Portnoy Law Firm

The Portnoy Law Firm has launched an investigation into possible securities fraud at Immix Biopharma after discovering that an executive operating under the alias 'Richard Graydon' was actually Ronald Fischer, a fugitive wanted in Rhode Island. The company terminated the officer on July 17, 2026, claiming the separation was unrelated to his activities. Following the disclosure, Immix's stock price declined approximately 10.83%.

GlobeNewswire Inc.

IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm

Block & Leviton is investigating Immix Biopharma for potential securities law violations after discovering that an executive operating under the name 'Richard Graydon' was actually a Rhode Island fugitive named Ronald Fischer using a false identity. The company terminated the individual on July 17, 2026, stating it was unrelated to his work activities. Immix shares fell approximately 10.83% following the news report.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.